Roberts et al. [71] have identified three categories of factors that correlate with shorter duration of response to venetoclax in CLL; they include: 1) bulky disease; 2) refractoriness to fludarabine or B-cell receptor pathway inhibitors (BCRi); 3) an adverse mutation profile (i.e., TP53 loss or mutation, NOTCH1 mutation, and IGHV unmutated status). Here, TP53 is linked to B-cell chronic lymphocytic leukemia.